Unnamed: 0,title,date,stock,sentiment
104755.0,78 Biggest Movers From Yesterday,2020-05-12 05:02:00-04:00,ATHX,neutral
104756.0,"Needham Maintains Buy on Athersys, Lowers Price Target to $5",2020-05-08 11:44:00-04:00,ATHX,negative
104757.0,Athersys Q1 EPS $(0.100) Misses $(0.080) Estimate,2020-05-07 17:00:00-04:00,ATHX,negative
104758.0,"The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500",2020-05-07 07:41:00-04:00,ATHX,negative
104759.0,33 Stocks Moving in Wednesday's Pre-Market Session,2020-05-06 07:15:00-04:00,ATHX,neutral
104760.0,"Athersys Announces Commencement Of Patient Enrollment In MACOVIA Study, A Pivotal Phase 2/3 Trial Evaluating MultiStem Cell Therapy For COVID-19 (Coronavirus)  Induced ARDS",2020-05-05 06:14:00-04:00,ATHX,neutral
104761.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,ATHX,neutral
104762.0,20 Healthcare Stocks Moving In Friday's Pre-Market Session,2020-05-01 07:42:00-04:00,ATHX,neutral
104763.0,32 Stocks Moving in Friday's Pre-Market Session,2020-05-01 07:15:00-04:00,ATHX,neutral
104764.0,Athersys Reports University Hospitals Cleveland Medical Center Now Open As Clinical Site For MACOVIA Coronavirus Trial,2020-05-01 06:16:00-04:00,ATHX,neutral
104765.0,81 Biggest Movers From Friday,2020-04-27 05:33:00-04:00,ATHX,neutral
104766.0,95 Biggest Movers From Friday,2020-04-20 05:00:00-04:00,ATHX,neutral
104767.0,70 Biggest Movers From Yesterday,2020-04-17 04:53:00-04:00,ATHX,neutral
104768.0,Mid-Afternoon Market Update: Rite Aid Falls On Wider Q4 Loss; ThermoGenesis Shares Gain,2020-04-16 14:31:00-04:00,ATHX,positive
104769.0,52 Stocks Moving In Thursday's Mid-Day Session,2020-04-16 12:58:00-04:00,ATHX,neutral
104770.0,52 Stocks Moving In Thursday's Mid-Day Session,2020-04-16 12:57:00-04:00,ATHX,neutral
104771.0,Mid-Day Market Update: NASDAQ Jumps 1.8%; Edison Nation Shares Spike Higher,2020-04-16 12:30:00-04:00,ATHX,positive
104772.0,Morning Market Stats in 5 Minutes,2020-04-16 10:21:00-04:00,ATHX,neutral
104773.0,Mid-Morning Market Update: Markets Mostly Lower; Morgan Stanley Misses Q1 Expectations,2020-04-16 10:13:00-04:00,ATHX,negative
104774.0,"The Daily Biotech Pulse: FDA Nod For UroGen, Novavax Coronavirus Vaccine To Enter Clinics, Soligenix Licenses Vaccine Adjuvant",2020-04-16 08:09:00-04:00,ATHX,neutral
104775.0,Athersys shares are trading lower after the company reported a common stock offering of 22.5 million shares at $2.25 per share.,2020-04-16 07:39:00-04:00,ATHX,positive
104776.0,33 Stocks Moving in Thursday's Pre-Market Session,2020-04-16 07:19:00-04:00,ATHX,neutral
104777.0,Athersys Prices 22.5M Share Public Offering of Common Stock @$2.25/Share,2020-04-16 05:47:00-04:00,ATHX,positive
104778.0,A Peek Into The Markets: US Stock Futures Gain Ahead Of Morgan Stanley Earnings,2020-04-16 05:37:00-04:00,ATHX,positive
104779.0,Hearing Athersys Offering Priced $2.25-$2.50/Share,2020-04-15 16:48:00-04:00,ATHX,neutral
104780.0,Athersys shares are trading lower after the company reported a $50 million common stock offering.,2020-04-15 16:34:00-04:00,ATHX,neutral
104781.0,Athersys Reports $50M Common Stock Offering,2020-04-15 16:27:00-04:00,ATHX,neutral
104782.0,"The Daily Biotech Pulse: Applied DNA Ships Vaccine Constructs For Animal Testing, Herceptin Biosimilar Now Available In US",2020-04-15 08:03:00-04:00,ATHX,neutral
104783.0,Athersys shares are trading higher after the company announced the FDA has authorized to initiate a Phase 2 clinical trial evaluating MultiStem Cell Therapy in trauma patients.,2020-04-15 07:12:00-04:00,ATHX,negative
104784.0,Athersys Announces FDA Authorizes Initiation Of Phase 2 Trial Evaluating MultiStem Cell Therapy In Trauma Patients,2020-04-15 06:09:00-04:00,ATHX,negative
104785.0,78 Biggest Movers From Yesterday,2020-04-15 04:45:00-04:00,ATHX,neutral
104786.0,55 Stocks Moving In Tuesday's Mid-Day Session,2020-04-14 12:52:00-04:00,ATHX,neutral
104787.0,86 Biggest Movers From Yesterday,2020-04-14 05:19:00-04:00,ATHX,negative
104788.0,63 Stocks Moving In Monday's Mid-Day Session,2020-04-13 12:35:00-04:00,ATHX,neutral
104789.0,"Biocept To Begin COVID-19 Testing; BioCryst, Athersys, Can-Fite To Research Potential Treatments In Clinics",2020-04-13 09:54:00-04:00,ATHX,neutral
104790.0,20 Healthcare Stocks Moving In Monday's Pre-Market Session,2020-04-13 07:39:00-04:00,ATHX,neutral
104791.0,Athersys shares are trading higher after the company announced the FDA has authorized the company to initiate a pivotal clinical trial evaluating MultiStem Cell Therapy in patients with coronavirus induced acute respiratory distress syndrome.,2020-04-13 07:17:00-04:00,ATHX,negative
104792.0,30 Stocks Moving in Monday's Pre-Market Session,2020-04-13 06:56:00-04:00,ATHX,neutral
104793.0,FDA Authorizes Athersys to Initiate a Pivotal Clinical Trial Evaluating MultiStem Cell Therapy in Patients With COVID-19 Induced Acute Respiratory Distress Syndrome,2020-04-13 06:03:00-04:00,ATHX,negative
104794.0,Shares of several healthcare companies are trading higher amid overall market strength. Several companies in the sector may also be benefiting from increased demand for therapies and medical supplies amid the coronavirus pandemic. UPDATE: Shares of some names in the sector moved higher later in the session following news that US Senator Sanders has suspended his presidential campaign.,2020-04-08 09:34:00-04:00,ATHX,positive
104795.0,74 Biggest Movers From Friday,2020-04-06 04:46:00-04:00,ATHX,neutral
104796.0,40 Stocks Moving In Friday's Mid-Day Session,2020-04-03 12:39:00-04:00,ATHX,neutral
104797.0,17 Healthcare Stocks Moving In Friday's Pre-Market Session,2020-04-03 07:38:00-04:00,ATHX,neutral
104798.0,25 Stocks Moving in Friday's Pre-Market Session,2020-04-03 07:15:00-04:00,ATHX,neutral
104799.0,76 Biggest Movers From Yesterday,2020-04-03 05:19:00-04:00,ATHX,neutral
104800.0,"Athersys shares are trading lower, potentially as traders circulate bearish blog post on the stock discussing the company's BARDA designation for MultiStem.",2020-04-02 15:19:00-04:00,ATHX,neutral
104801.0,60 Stocks Moving In Thursday's Mid-Day Session,2020-04-02 12:40:00-04:00,ATHX,neutral
104802.0,Traders Circulate Bearish Blog Post On Athersys (Link),2020-04-02 12:23:00-04:00,ATHX,neutral
104803.0,72 Biggest Movers From Yesterday,2020-04-02 04:23:00-04:00,ATHX,neutral
104804.0,20 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-04-01 07:45:00-04:00,ATHX,neutral
104805.0,"The Daily Biotech Pulse: InflaRx Begins Human Testing For COVID-induced Pneumonia, Chembio, Becton Dickinson Launch Coronavirus Tests",2020-04-01 07:38:00-04:00,ATHX,neutral
104806.0,"The Daily Biotech Pulse: Amarin Faces Legal Setback, Milestone Payment Kicks In For CytomX, Savara, Reata Disclose COVID-19 Disruptions",2020-03-31 08:26:00-04:00,ATHX,negative
104807.0,80 Biggest Movers From Yesterday,2020-03-31 04:15:00-04:00,ATHX,neutral
104808.0,55 Stocks Moving In Monday's Mid-Day Session,2020-03-30 12:49:00-04:00,ATHX,neutral
104809.0,Mid-Morning Market Update: Markets Open Higher; Cal-Maine Foods Profit Tops Expectations,2020-03-30 10:10:00-04:00,ATHX,positive
104810.0,Athersys shares are trading higher after HEALIOS K.K. bought 4 million shares at an average price of $1.76 per share.,2020-03-30 08:22:00-04:00,ATHX,positive
104811.0,"HEALIOS K.K. Healios Purchased 4,000,000 Shares in Athersys at $1.76/Share by Fully Exercising Warrant to Acquire Additional Shares",2020-03-30 06:13:00-04:00,ATHX,positive
104812.0,18 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2020-03-24 07:36:00-04:00,ATHX,neutral
104813.0,Stocks That Hit 52-Week Highs On Friday,2020-03-20 14:26:00-04:00,ATHX,neutral
104814.0,Shares of several healthcare companies are trading higher as the market rebounds from coronavirus-related selloffs.,2020-03-20 09:43:00-04:00,ATHX,positive
104815.0,"Athersys Earlier Appoints Maia Hansen To Senior Vice President, Operations and Supply Chain",2020-03-19 09:43:00-04:00,ATHX,neutral
104816.0,18 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2020-03-17 08:58:00-04:00,ATHX,neutral
104817.0,"Athersys Shares Higher, Hearing Needham Raises PT To $12 And Says BARDA Has Designated MultiStem As 'highly relevant' For Addressing Coronavirus Outbreak; Unconfirmed",2020-03-17 08:12:00-04:00,ATHX,positive
104818.0,"Athersys Q4 EPS $(0.06) Beats $(0.08) Estimate, Sales $300K Miss $790K Estimate",2020-03-16 16:06:00-04:00,ATHX,negative
104819.0,"The Week Ahead In Biotech: COVID-19 Updates, Tapering Earnings Flow, Eton's Seizure Drug Review",2020-03-15 09:55:00-04:00,ATHX,neutral
104820.0,20 Healthcare Stocks Moving In Monday's Session,2020-03-09 13:40:00-04:00,ATHX,neutral
104821.0,20 Biotechnology Stocks Moving In Tuesday's After-Market Session,2020-01-21 23:35:00-05:00,ATHX,neutral
104822.0,29 Healthcare Stocks Moving In Tuesday's After-Market Session,2020-01-21 23:28:00-05:00,ATHX,neutral
104823.0,"The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance",2020-01-15 08:22:00-05:00,ATHX,negative
104824.0,Athersys Names Ivor Macleod Chief Financial Officer,2020-01-15 06:00:00-05:00,ATHX,neutral
104825.0,Athersys Provides Update On One-Year ARDS Study Data; Says 'an evaluation of quality-of-life over the one-year period suggests further potential benefits from MultiStem treatment.',2020-01-14 06:08:00-05:00,ATHX,positive
104826.0,"The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic",2019-12-19 07:52:00-05:00,ATHX,negative
104827.0,Stocks That Hit 52-Week Lows On Wednesday,2019-12-18 13:51:00-05:00,ATHX,negative
104828.0,"The Daily Biotech Pulse: Positive Adcom Verdict For Merck, Homology Medicine Slips On Mixed Gene Therapy Efficacy Data",2019-12-18 07:23:00-05:00,ATHX,positive
104829.0,Athersys Enters 31M Share Stock Purchase Agreement With Aspire Capital Fund,2019-11-26 16:45:00-05:00,ATHX,positive
104830.0,"Athersys, Announces Healios Receives Notification of Orphan Designation  for Acute Respiratory Distress Syndrome Clinical Program in Japan",2019-11-14 06:05:00-05:00,ATHX,negative
104831.0,"Athersys Q3 EPS $(0.08) Beats $(0.09) Estimate, Sales $361K Miss $1.47M Estimate",2019-11-06 16:52:00-05:00,ATHX,negative
104832.0,"The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings",2019-11-06 08:21:00-05:00,ATHX,positive
104833.0,Athersys Shares Spike To Session High On Volume; Traders Circulate Seeking Alpha Blog Post From Skylar Florian 'Athersys: Potential Upside',2019-09-23 10:46:00-04:00,ATHX,positive
104834.0,"Benzinga's Top Upgrades, Downgrades For August 26, 2019",2019-08-26 09:37:00-04:00,ATHX,positive
104835.0,"Dawson James Initiates Coverage On Athersys with Buy Rating, Announces $11 Price Target",2019-08-26 08:32:00-04:00,ATHX,neutral
104836.0,42 Healthcare Stocks Moving In Wednesday's After-Market Session,2019-08-07 21:24:00-04:00,ATHX,neutral
104837.0,"Athersys Q2 EPS $(0.06) Beats $(0.09) Estimate, Sales $4.262M Beat $1.47M Estimate",2019-08-07 16:46:00-04:00,ATHX,neutral
104838.0,40 Healthcare Stocks Moving In Thursday's After-Market Session,2019-08-02 04:10:00-04:00,ATHX,neutral
104839.0,45 Healthcare Stocks Moving In Monday's After-Market Session,2019-07-30 04:54:00-04:00,ATHX,neutral
104840.0,40 Healthcare Stocks Moving In Friday's After-Market Session,2019-07-29 04:25:00-04:00,ATHX,neutral
104841.0,"'$ATHX is using the story of a stroke survivor to promote the development of an experimental stem cell therapy. But by doing so, the company has obscured the treatment's clinical trial failure' -STAT's Adam Feuerstein",2019-06-26 07:40:00-04:00,ATHX,negative
104842.0,Athersys 8-K Shows Co. Entered Open Market Sale Deal With Jefferies For $50M In Common Stock,2019-05-30 17:19:00-04:00,ATHX,neutral
104843.0,Athersys Announces Additional Favorable Data From Its Exploratory Phase 1/2 Acute Respiratory Distress Syndrome Clinical Trial; The Multistem Treatment Group Had More Ventilator-Free And Icu-Free Days,2019-05-20 12:23:00-04:00,ATHX,negative
104844.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs",2019-05-18 09:50:00-04:00,ATHX,neutral
104845.0,58 Biggest Movers From Yesterday,2019-05-15 05:09:00-04:00,ATHX,neutral
104846.0,40 Stocks Moving In Tuesday's Mid-Day Session,2019-05-14 12:43:00-04:00,ATHX,neutral
104847.0,26 Stocks Moving In Tuesday's Pre-Market Session,2019-05-14 08:02:00-04:00,ATHX,neutral
104848.0,A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street,2019-05-14 07:03:00-04:00,ATHX,neutral
104849.0,Athersys Receives FDA Fast Track Designation For Its MultiStem Program For Acute Respiratory Distress Syndrome,2019-05-14 06:11:00-04:00,ATHX,negative
104850.0,Athersys Announces Fast Track Designation From FDA for MultiStem® Program for Acute Respiratory Distress Syndrome,2019-05-14 06:03:00-04:00,ATHX,negative
104851.0,"Athersys Q1 EPS $(0.09) Misses $(0.08) Estimate, Sales $1.445M Miss $1.45M Estimate",2019-05-08 17:06:00-04:00,ATHX,negative
104852.0,"The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split",2019-05-08 07:53:00-04:00,ATHX,negative
104853.0,Mid-Afternoon Market Update: Dow Rises Over 100 Points; Akari Therapeutics Shares Spike Higher,2019-04-23 14:41:00-04:00,ATHX,positive
104854.0,"Athersys Reports Its Partner HEALIOS Enrolled First Patient In ONE-BRIDGE Study In Japan, No Terms Disclosed",2019-04-23 06:12:00-04:00,ATHX,negative
104855.0,"Athersys Q4 EPS $(0.08), Inline, Sales $1.51M Beat $1.47M Estimate",2019-03-14 17:06:00-04:00,ATHX,neutral
104856.0,"The Daily Biotech Pulse: Arsanis Completes X4 Merger, EC Nod For Roche, Axovant Offering",2019-03-14 07:47:00-04:00,ATHX,neutral
104857.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Thurs., Jan. 24, 2019",2019-01-24 07:50:00-05:00,ATHX,positive
104858.0,54 Biggest Movers From Yesterday,2019-01-24 05:04:00-05:00,ATHX,neutral
104859.0,40 Stocks Moving In Wednesday's Mid-Day Session,2019-01-23 12:27:00-05:00,ATHX,neutral
104860.0,Mid-Day Market Update: Accuray Jumps Following Strong Q2 Results; Rexahn Pharmaceuticals Shares Slide,2019-01-23 12:01:00-05:00,ATHX,positive
104861.0,Athersys shares are trading higher after the company announced positive results from its exploratory clinical study of MultiStem cell therapy.,2019-01-23 09:26:00-05:00,ATHX,positive
104862.0,Athersys Announces 'Positive' Results From Its Exploratory Clinical Study of MultiStem Cell Therapy for Treatment of Acute Respiratory Distress Syndrome,2019-01-23 06:07:00-05:00,ATHX,negative
104863.0,Athersys Announces Healios Agrees to Make $2M Payment to Extend Exclusive Period for Negotiating an Option for a License to Multistem® Therapy for Indications in China,2018-12-17 06:08:00-05:00,ATHX,positive
104864.0,"Athersys, Inc. Q3 EPS $(0.07), Inline, Sales $2.321M Beat $1.96M Estimate",2018-11-06 16:52:00-05:00,ATHX,neutral
104865.0,"Athersys Q2 EPS $0.05 Up From $(0.06) YoY, Sales $19.391M Beat $11.28M Estimate",2018-08-07 17:09:00-04:00,ATHX,neutral
104866.0,"The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel",2018-08-07 08:23:00-04:00,ATHX,negative
104867.0,Athersys Announces Enrollment Of First Patient In Masters-2 Phase 3 Study Of Multistem Treatment For Ischemic Stroke,2018-07-31 06:06:00-04:00,ATHX,neutral
104868.0,48 Biggest Movers From Yesterday,2018-06-20 03:55:00-04:00,ATHX,neutral
104869.0,23 Stocks Moving In Thursday's Pre-Market Session,2018-06-14 08:00:00-04:00,ATHX,neutral
104870.0,44 Biggest Movers From Yesterday,2018-06-12 04:49:00-04:00,ATHX,neutral
104871.0,32 Stocks Moving In Monday's Mid-Day Session,2018-06-11 12:25:00-04:00,ATHX,neutral
104872.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Fri., Jun. 8, 2018",2018-06-08 12:57:00-04:00,ATHX,positive
104873.0,36 Stocks Moving In Thursday's Mid-Day Session,2018-06-07 12:30:00-04:00,ATHX,neutral
104874.0,Benzinga Pro's 5 Stocks To Watch Today,2018-06-07 08:41:00-04:00,ATHX,neutral
104875.0,27 Stocks Moving In Thursday's Pre-Market Session,2018-06-07 08:20:00-04:00,ATHX,neutral
104876.0,UPDATE: Athersys To Receive $20M In License Fees And Up To $360M In Milestones,2018-06-07 06:13:00-04:00,ATHX,neutral
104877.0,Athersys Announces Expansion Of Collaboration With Healios; Healios To Obtain Licenses For Development And Commercialization In Japan Of MultiStem For ARDS,2018-06-07 06:12:00-04:00,ATHX,neutral
104878.0,"Benzinga's Daily Biotech Pulse: Vascular Biogenics Soars On Positive Platform Data, Axovant Licenses Parkinson's Candidate",2018-06-06 08:38:00-04:00,ATHX,positive
104879.0,"Benzinga's Daily Biotech Pulse: Mylan's Neulasta Biosimilar Approved, Portola's CEO To Retire, Regenxbio To Join S&P SmallCap Index",2018-06-05 08:05:00-04:00,ATHX,positive
104880.0,"On June 4th, Athersys And Healios Agreed To Further Extended Period Negotiation Collaboration Expansion To June 6th",2018-06-05 07:23:00-04:00,ATHX,positive
104881.0,"Benzinga's Daily Biotech Pulse: FDA Panel Nod For Akcea, Synergy's Revenue Miss, FDA Warns E-Liquid Makers Again",2018-05-11 08:21:00-04:00,ATHX,negative
104882.0,"Athersys Q1 EPS $(0.08) Beats $(0.09) Estimate, Sales $1.066M Beat $1.04M Estimate",2018-05-10 17:12:00-04:00,ATHX,neutral
104883.0,"Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results",2018-05-10 09:44:00-04:00,ATHX,neutral
104884.0,"The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More",2018-05-06 18:19:00-04:00,ATHX,neutral
104885.0,"'New review paper - ""Intravenous Cellular Therapies for Acute Ischemic Stroke"" published in Stroke @StrokeAHA_ASA by Dr. Robert Mays of $ATHX and Dr. Sean Savitz @UTHealth #Stroke #MultiStem'-Athersys Tweet",2018-04-19 15:02:00-04:00,ATHX,neutral
104886.0,45 Biggest Movers From Yesterday,2018-03-14 04:55:00-04:00,ATHX,neutral
104887.0,"Athersys Reports Q4 EPS $(0.11) vs $(0.07) Est., Sales $1.17M vs $420K Est.",2018-03-13 16:28:00-04:00,ATHX,neutral
104888.0,Athersys Shares Up 16.4% After $1.76/Share Equity Investment From HEALIOS,2018-03-13 13:01:00-04:00,ATHX,positive
104889.0,"Athersys Shares Up 16.7% After $1.76/Share Equity Investment From HEALIOS, Total Of $21M",2018-03-13 12:55:00-04:00,ATHX,positive
104890.0,35 Stocks Moving In Tuesday's Mid-Day Session,2018-03-13 12:28:00-04:00,ATHX,neutral
104891.0,Benzinga Pro's 5 Stock To Watch Today,2018-03-13 08:12:00-04:00,ATHX,neutral
104892.0,Athersys to Receive a $21M Equity Investment at $1.76/Share From HEALIOS and $10M in Escrow to Expand Healios' License to Develop MultiStem,2018-03-13 06:11:00-04:00,ATHX,positive
104893.0,Athersys and Healios Announce Binding LoI to Expand MultiStem Collaboration; Healios Investing ~$21M @ $1.76/Share,2018-03-13 05:21:00-04:00,ATHX,positive
104894.0,"The Week Ahead In Biotech: Earnings, PDUFA Dates And More",2018-03-11 16:58:00-04:00,ATHX,neutral
104895.0,Athersys S-3 Filing Shows Registration For 24.7M Share Common STock Offering Via Selling Holders,2018-02-02 09:08:00-05:00,ATHX,positive
104896.0,Athersys Enters Into New $100M Equity Facility with Aspire Capital,2018-02-02 06:04:00-05:00,ATHX,neutral
104897.0,Athersys 8-K Shows Common Stock Purchase Deal With Aspire Capital Fund For $100M,2018-02-01 17:29:00-05:00,ATHX,neutral
104898.0,Athersys Reports HEALIOS Enrollment Of First Patient In Japan In TREASURE Study Of MultiStem Treatment For Ischemic Stroke,2017-11-15 10:06:00-05:00,ATHX,positive
104899.0,"Athersys Reports Q3 EPS $(0.06), Inline, Sales $400K vs $600K Est.",2017-11-08 16:23:00-05:00,ATHX,neutral
104900.0,28 Stocks Moving In Monday's Pre-Market Session,2017-10-16 08:17:00-04:00,ATHX,neutral
104901.0,"Athersys Says Entered into Agreement with Garnet On October 12, 2017 to Settle Longstanding Intellectual Property Disagreements -8-K",2017-10-16 06:15:00-04:00,ATHX,positive
104902.0,28 Stocks Moving In Friday's Pre-Market Session,2017-10-13 08:03:00-04:00,ATHX,neutral
104903.0,30 Stocks Moving In Thursday's Pre-Market Session,2017-10-12 08:03:00-04:00,ATHX,neutral
104904.0,28 Stocks Moving In Wednesday's Mid-Day Session,2017-10-11 12:19:00-04:00,ATHX,neutral
104905.0,25 Stocks Moving In Wednesday's Pre-Market Session,2017-10-11 08:22:00-04:00,ATHX,neutral
104906.0,"Athersys, Nikon CeLL Innovation to Collaborate on MultiStem Commercial Manufacturing in Japan",2017-10-11 06:03:00-04:00,ATHX,positive
104907.0,12 Biggest Mid-Day Losers For Tuesday,2017-10-10 12:34:00-04:00,ATHX,negative
104908.0,Mid-Day Market Update: Crude Oil Up 2.7%; MannKind Shares Spike Higher,2017-10-10 12:09:00-04:00,ATHX,negative
104909.0,Mid-Morning Market Update: Markets Open Higher; Wal-Mart Reports $20B Buyback Plan,2017-10-10 10:14:00-04:00,ATHX,neutral
104910.0,Athersys Announces RMAT Designation From FDA,2017-10-05 08:02:00-04:00,ATHX,neutral
104911.0,"Athersys Reports Q2 EPS $(0.06) vs $(0.07) Est., Sales $700K vs $550K Est.",2017-08-09 16:16:00-04:00,ATHX,neutral
104912.0,Athersys Says it Got a Positive Opinion from the European Medicines Agency for MiltiStem,2017-08-07 06:18:00-04:00,ATHX,positive
104914.0,"Athersys Reports Q1 EPS $(0.06) vs $(0.07) Est., Sales $1.5M vs $640K Est.",2017-05-09 17:25:00-04:00,ATHX,neutral
104915.0,Adam Feuerstein Tweets: The $ATHX stroke study failed.,2017-04-06 15:55:00-04:00,ATHX,negative
104916.0,15 Biggest Mid-Day Losers For Friday,2017-03-31 12:41:00-04:00,ATHX,negative
104917.0,18 Biggest Mid-Day Gainers For Wednesday,2017-03-29 12:46:00-04:00,ATHX,neutral
104918.0,22 Stocks Moving In Wednesday's Pre-Market Session,2017-03-29 08:39:00-04:00,ATHX,neutral
104919.0,William Blair Initiates Coverage On Athersys at Outperform,2017-03-28 16:37:00-04:00,ATHX,neutral
104920.0,Athersys Pops to High of $1.38 After-Hours,2017-03-28 16:23:00-04:00,ATHX,neutral
104921.0,Athersys Pops to High of $1.20 on Volume,2017-03-23 10:06:00-04:00,ATHX,neutral
104922.0,"Athersys Reports Q4 EPS $(0.10) vs. $(0.08) Est., Sales $983K vs. $420K",2017-03-09 16:29:00-05:00,ATHX,neutral
104923.0,"Benzinga's Top Upgrades, Downgrades For February 7, 2017",2017-02-07 09:30:00-05:00,ATHX,positive
104924.0,Athersys Shares Up 12.07% Pre-market,2017-02-07 08:47:00-05:00,ATHX,positive
104925.0,"Needham Initiates Coverage On Athersys At Buy, Announces $7 Price Target",2017-02-07 07:59:00-05:00,ATHX,neutral
104926.0,"ATHERSYS, INC / NEW: Campbell Laura K (Senior Vice Pres Finance) Buys 20,000 @ Avg Price: $1.01 (Form4)",2017-02-01 09:24:00-05:00,ATHX,neutral
104927.0,Mid-Afternoon Market Update: Celestica Rises On Earnings Beat; KEYW Shares Slide,2017-01-27 15:41:00-05:00,ATHX,positive
104928.0,20 Biggest Mid-Day Losers For Friday,2017-01-27 13:16:00-05:00,ATHX,negative
104929.0,Mid-Day Market Update: Crude Oil Down 2%; Stonegate Mortgage Shares Spike Higher,2017-01-27 12:21:00-05:00,ATHX,negative
104930.0,Mid-Morning Market Update: Markets Mostly Flat; Alphabet Profit Misses Views,2017-01-27 09:46:00-05:00,ATHX,positive
104931.0,Athersys Announces Pricing of Public Offering of 19.8M Common Stock At $1.01/Share,2017-01-27 09:00:00-05:00,ATHX,neutral
104932.0,"Athersys Reports Proposed Public Offering of Common Stock, Size Not Disclosed",2017-01-26 16:39:00-05:00,ATHX,neutral
104933.0,"Athersys Reports ReGenesys Unit Has Entered Research, Option Deal for Cell Therapy",2017-01-18 06:01:00-05:00,ATHX,neutral
104934.0,"Athersys Reports Q3 EPS $(0.07) vs. Est. $(0.10), Rev. $311K vs. Est. $560K",2016-11-09 16:04:00-05:00,ATHX,neutral
104935.0,Athersys Gets Approval For Phase 3 Study of MultiStem Under Special Protocol Assessment,2016-09-28 06:31:00-04:00,ATHX,positive
104936.0,Athersys Gets Approval for Clinical Trial in Japan for Ischemic Stroke with MultiStem,2016-09-12 06:32:00-04:00,ATHX,positive
104937.0,"Athersys Reports Q2 EPS $(0.08) vs. Est. $(0.10), Rev. $595K vs. Est. $320K",2016-08-09 16:47:00-04:00,ATHX,neutral
104938.0,Athersys Reports Q1 EPS $(0.06) Vs Est $(0.08),2016-05-05 17:33:00-04:00,ATHX,neutral
104939.0,Mid-Afternoon Market Update: FormFactor Drops On Weak Forecast; ConforMIS Shares Gain,2016-03-30 14:31:00-04:00,ATHX,positive
104940.0,Mid-Day Market Update: ACADIA Pharmaceuticals Rises Following FDA Panel Vote; Verint Systems Shares Slide,2016-03-30 12:05:00-04:00,ATHX,positive
104941.0,Mid-Afternoon Market Update: US Stocks Gain; Sunedison Shares Tumble,2016-03-22 15:13:00-04:00,ATHX,positive
104942.0,"Athersys Reports Q4 EPS $0.04 vs $(0.08) in Same Qtr. Last Year, Sales $10.605M",2016-03-10 16:17:00-05:00,ATHX,neutral
104943.0,One-Year Results From Phase 2 Stroke Study of MultiStem Cell Therapy Demonstrate a Significantly Higher Rate of Complete or Nearly Full Recovery Compared To Placebo Subjects,2016-02-17 17:00:00-05:00,ATHX,neutral
104944.0,Mid-Afternoon Market Update: Dow Slides 100 Points; Container Store Shares Down On Weak Results,2016-01-08 15:40:00-05:00,ATHX,negative
104945.0,Mid-Day Market Update: US Stocks Turn Lower; NGL Energy Partners Shares Spike Higher,2016-01-08 11:59:00-05:00,ATHX,positive
104946.0,"Healios, Athersys Report Deal Related to Regenerative Medicine for Treatment of Stroke Using MultiStem Therapy",2016-01-08 06:05:00-05:00,ATHX,neutral
104947.0,"Healios, Athersys Announce Regenerative Medicine Partnership for Treatment of Stroke Using MultiStem Therapy",2016-01-08 04:16:00-05:00,ATHX,neutral
104948.0,"Athersys Says Aspire Capital is Committed to Purchase Up to Aggregate of $30M of Company's Common Stock; Athersys  Issued to Aspire Capital 250,000 Shares of Common Stock",2015-12-18 16:48:00-05:00,ATHX,positive
104949.0,Athersys' MultiStem Promotes Recovery After Acute Spinal Cord Injury in Preclinical Study,2015-11-19 05:51:00-05:00,ATHX,negative
104950.0,"Athersys Reports Q3 EPS $(0.08) vs $(0.07) Est., Sales $400K",2015-11-05 17:16:00-05:00,ATHX,neutral
104951.0,"Athersys, Chugai End License Agreement For Exclusive Development, Commercialization of Multistem Cell Therapy for Ischemic Stroke in Japan",2015-10-21 06:32:00-04:00,ATHX,positive
104952.0,Athersys Reports Q2 Loss $0.01 Vs Est $0.08,2015-08-06 17:31:00-04:00,ATHX,negative
104953.0,Piper Jaffray Downgrades Athersys to Neutral,2015-07-09 10:59:00-04:00,ATHX,neutral
104954.0,Morning Market Losers,2015-05-12 09:50:00-04:00,ATHX,negative
104955.0,"Athersys Reports Q1 Loss $0.16 Vs Est Loss $0.09, Revs $731K Vs Est $2.01M",2015-05-11 16:08:00-04:00,ATHX,negative
104956.0,Adam Feuerstein Is A Skeptic Of Stem Cell Therapy,2015-04-18 10:46:00-04:00,ATHX,negative
104957.0,Morning Market Losers,2015-04-17 09:56:00-04:00,ATHX,negative
104958.0,"UPDATE: Atherys Reports Cell Therapy did Not Show Difference at 90 Days Compared to Placebo With Respect to Primary, Secondary Endpoints",2015-04-17 06:03:00-04:00,ATHX,positive
104959.0,Athersys Announces Results From Phase 2 Study of MultiStem Cell Therapy for Treatment of Ischemic Stroke,2015-04-17 06:01:00-04:00,ATHX,neutral
104960.0,Maxim Sees Major Upside In These Biotech Stocks,2015-03-14 14:12:00-04:00,ATHX,neutral
104961.0,"Athersys Reports Q4 EPS $(0.08) vs. Est. $(0.10), Rev. $235K vs. Est $430K",2015-03-12 16:07:00-04:00,ATHX,neutral
104962.0,Morning Market Gainers,2015-03-02 09:45:00-05:00,ATHX,neutral
104963.0,Why Investors Are Watching Athersys Ahead Of Stem Cell Data,2015-02-04 12:52:00-05:00,ATHX,neutral
104964.0,7 U.S. Health Care Penny Stocks With Upside Potential Greater Than 100%,2015-02-02 08:21:00-05:00,ATHX,positive
104965.0,Option Alert: Athersys Apr $5 Call; 1490 Contract Trade at Ask @$0.20,2015-01-26 12:42:00-05:00,ATHX,positive
104966.0,"Athersys Cell Therapy, Catapult Announce Grant to Support Clinical Development of Stem Cell Therapy for Severe Acute Respiratory Condition",2015-01-22 07:01:00-05:00,ATHX,positive
104967.0,What Investors Are Looking At In The Stem Cell Sector,2015-01-13 11:48:00-05:00,ATHX,neutral
104968.0,What Investors Are Looking For In Brainstorm Cell Therapeutics' Upcoming Clinical Results,2014-12-31 16:02:00-05:00,ATHX,neutral
104969.0,US Stock Futures Down; Crude Oil Rises,2014-12-29 07:00:00-05:00,ATHX,negative
104970.0,Athersys Finishes Enrollment of Phase 2 Study of MultiStem(R) Cell Therapy for Ischemic Stroke,2014-12-29 06:33:00-05:00,ATHX,neutral
104971.0,Athersys Shares Move Higher Ahead of Friday JUNO IPO,2014-12-18 10:17:00-05:00,ATHX,positive
104972.0,"Athersys, Inc. Reports Q3 EPS of $(0.06) vs $(0.09) Est; Revenue of $293.0K vs $490.0K Est",2014-11-10 16:13:00-05:00,ATHX,neutral
104973.0,"Events for the Week of Oct. 13-17, 2014",2014-10-14 15:39:00-04:00,ATHX,neutral
104974.0,"Athersys, Inc. Reports Q2 EPS of $(0.04) vs $(0.09) Est; Revenue of $388.0K vs $610.0K Est",2014-08-11 16:30:00-04:00,ATHX,neutral
104975.0,"Athersys, Inc. Reports Q1 EPS of $(0.15) vs $(0.10) Est; Revenue of $707.0K vs $660.0K Est",2014-05-08 16:40:00-04:00,ATHX,neutral
104976.0,"Athersys Shares Jump 5+% as First Analysis Initiates with Overweight Rating, $5 Target",2014-04-29 12:45:00-04:00,ATHX,negative
104977.0,Stocks Hitting 52-Week Lows,2014-04-28 10:38:00-04:00,ATHX,negative
104978.0,Morning Market Losers ,2014-04-28 09:51:00-04:00,ATHX,negative
104979.0,Benzinga's Top #PreMarket Losers,2014-04-28 08:09:00-04:00,ATHX,negative
104980.0,UPDATE: Athersys Shares Fall 50% Premarket on Failed Trial Results ,2014-04-28 07:36:00-04:00,ATHX,negative
104981.0,"UPDATE: Athersys Issues Phase 2 Study Results of Multistem Cell Therapy for UC, Failed to Show Meaningful Benefit, Efficacy",2014-04-28 07:22:00-04:00,ATHX,positive
104982.0,PREVIEW: Athersys to Resume Trading at 7:30AM ET,2014-04-28 07:15:00-04:00,ATHX,neutral
104983.0,"Athersys Issues Phase 2 Study Results of Multistem Cell Therapy for UC, Failed to Show Meaningful Benefit, Efficacy",2014-04-28 07:14:00-04:00,ATHX,positive
104984.0,Athersys Halted; Pending News,2014-04-28 07:00:00-04:00,ATHX,neutral
104985.0,"Athersys Files 20M Stock, Warrants Shelf",2014-03-13 16:20:00-04:00,ATHX,neutral
104986.0,"Athersys, Inc. Reports Q4 EPS of $(0.15) vs $(0.08) Est; Revenue of $920.0K vs $1.81M Est",2014-03-13 16:17:00-04:00,ATHX,neutral
104987.0,"Athersys Granted New Patents in Japan for Stem Cell, Regenerative Medicine Technology ",2014-01-09 07:05:00-05:00,ATHX,positive
104988.0,Target on Athersys Boosted from $6 to $10 at Maxim,2013-12-19 14:46:00-05:00,ATHX,positive
104989.0,Athersys Confirms Completion of Patient Enrollment of Pfizer's Phase II Study of MultiStem Cell Therapy for Ulcerative Colitis,2013-12-19 07:10:00-05:00,ATHX,neutral
104990.0,Athersys MultiStem Stem Cell Therapy Receives Orphan Drug Designation in Europe,2013-12-17 07:01:00-05:00,ATHX,neutral
104991.0,"Athersys Prices Direct Offering of Stock, Warrants, Gross Proceeds Expected at $20M",2013-11-27 14:01:00-05:00,ATHX,negative
104992.0,"Athersys, Inc. Reports Q3 EPS of $(0.10) vs $(0.12) Est; Revenue of $621.0K vs $390.0K Est",2013-11-14 16:08:00-05:00,ATHX,neutral
104993.0,Athersys May Offer U p to 10M Shares,2013-11-08 16:37:00-05:00,ATHX,positive
104994.0,"Athersys, Inc. Reports Q2 EPS of $(0.01) vs $(0.12) Est; Revenue of $571.0K vs $390.0K Est",2013-08-13 16:09:00-04:00,ATHX,neutral
104995.0,"Earnings Scheduled For May 14, 2013 ",2013-05-14 05:02:00-04:00,ATHX,neutral
104996.0,Athersys Announces Authorization of Stem Cell Clinical Trial for Stroke in the UK,2013-04-17 13:15:00-04:00,ATHX,neutral
104997.0,"Athersys, Inc. Reports Q4 EPS of $(0.07) vs $(0.10) Est; Revenue of $2.29M vs $1.71M Est",2013-03-12 16:06:00-04:00,ATHX,neutral
104998.0,Athersys Prices 19.8M Shares at $1.01,2012-10-26 09:18:00-04:00,ATHX,positive
104999.0,Athersys Reports MultiStem Treatment May Reduce Inflammation and Promote Reparative Processes Following Acute Brain Injury ,2012-10-10 07:13:00-04:00,ATHX,negative
105000.0,Athersys Presents Research Results from MS Program ,2012-10-05 07:14:00-04:00,ATHX,neutral
105001.0,Athersys Reports Q2 EPS $-0.13 vs $-0.14 Est; Revenues $2.66M vs $2.46M Est,2012-08-13 16:06:00-04:00,ATHX,neutral
105002.0,"Earnings Scheduled For August 13, 2012",2012-08-13 00:26:00-04:00,ATHX,neutral
105003.0,Earnings Scheduled For May 14,2012-05-14 02:12:00-04:00,ATHX,neutral
105004.0,Athersys Announces Meeting With FDA to Discuss Advancing Clinical Development of MultiStem for the Prevention of GvHD  ,2012-04-27 07:08:00-04:00,ATHX,neutral
105005.0,Atherys Files to Sell 8.69M Shares of Common Stock -Filing,2012-03-28 16:30:00-04:00,ATHX,positive
105006.0,Earnings Scheduled For March 27,2012-03-27 04:05:00-04:00,ATHX,neutral
105007.0,UPDATE: Piper Jaffray Initiates Coverage on Athersys,2012-03-20 07:26:00-04:00,ATHX,neutral
105008.0,"Piper Jaffray Initiates Coverage on Athersys at Overweight, Announces PT of $4",2012-03-20 06:46:00-04:00,ATHX,negative
105009.0,From Earlier: Athersys Announces Private Placement Financing for $9M; Will Issue 4.35M Shares,2012-03-09 09:33:00-05:00,ATHX,positive
105010.0,Positive Data Presented on Athersys' MultiStem to Treat Stroke ,2012-02-03 10:52:00-05:00,ATHX,positive
105011.0,Athersys Trading 19.3% Higher on Heavy Volume; Currently at $2.23,2012-02-01 15:01:00-05:00,ATHX,neutral
105012.0,Athersys Announces Positive Results of MultiStem Clinical Trial for Hematopoietic Stem Cell Transplant Support and Prevention of Graft-Versus-Host Disease  ,2012-02-01 15:00:00-05:00,ATHX,positive
105013.0,Athersys Awarded $3.6 Million in Grant Funding for Stem Cell Product Development  ,2012-02-01 07:09:00-05:00,ATHX,positive
105014.0,Athersys Receives U.S. Patent Covering the Treatment of Cardiovascular Disease With Adult Stem Cells ,2012-01-04 07:02:00-05:00,ATHX,neutral
105015.0,"Microcap Movers for Friday December 2 , 2011",2011-12-02 17:46:00-05:00,ATHX,neutral
105016.0,Athersys Enters Into $20 Million Equity Purchase Agreement With Aspire Capital ,2011-11-14 07:01:00-05:00,ATHX,positive
105017.0,Athersys Confirms Completion of Patient Enrollment for Its Phase I Study of MultiStem for Hematopoietic Stem Cell Transplant Support  ,2011-10-17 07:03:00-04:00,ATHX,positive
105018.0,Athersys Announces Positive Interim Results From Ongoing Phase I Study of MultiStem(R) ,2011-05-25 07:03:00-04:00,ATHX,positive
105019.0,Athersys Announces Registered $13.1 Million Offering,2011-01-28 09:21:00-05:00,ATHX,neutral
105020.0,Athersys Jumps On Patent News (ATHX),2010-12-28 10:00:00-05:00,ATHX,neutral
105021.0,ATHX Up Following Positive Results For Multistem,2010-09-20 13:51:00-04:00,ATHX,positive
105022.0,"Pfizer Deal Enhances Compugen Share Price, (CGEN, PFE, ATHX)",2009-12-23 12:32:00-05:00,ATHX,positive
105023.0,"Benzinga’s Biggest Losers (CTAS, ATHX, MTG, AHD, YRCW)",2009-12-23 11:39:00-05:00,ATHX,negative
105024.0,"Benzinga’s Top Upgrades (AHD, AMTD, IAG, XXIA, ATHX, SAIA)",2009-12-22 09:06:00-05:00,ATHX,positive
105025.0,Pfizer (PFE) And Athersys (ATHX) Enter Into Drug Development Deal,2009-12-21 14:22:00-05:00,ATHX,neutral
105026.0,"Company News for December 21, 2009 - Corporate Summary",2009-12-21 09:17:00-05:00,ATHX,neutral
105027.0,"Benzinga’s Top Pre- Market Gainers (CHTT, BUCY, SGEN, INCY, MAIL, ATHX)",2009-12-21 08:25:00-05:00,ATHX,positive
105028.0,"Benzinga’s News Roundup (AIG, ATHX, NOK, INTC, SNY, WAG, CAG)",2009-12-21 08:06:00-05:00,ATHX,negative
